IP Library Granted Patent US 9,180,187
Granted Patent B2
US 9,180,187 · App. 13/576,950 · Granted Nov 10, 2015

Medicament for treating and/or preventing cancer

Inventors: Takayoshi Ido (Kanagawa, JP); Fumiyoshi Okano (Kanagawa, JP); Yoshinori Narita (Kanagawa, JP)
Assignee: TORAY INDUSTRIES, INC.
A61K39/39558
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,180,187
App. No.
13/576,950
Granted
Nov 10, 2015
Kind
B2
Abstract

This invention relates to a medicament for treating and/or preventing a cancer, comprising a combination of an antibody against a cancer antigen CAPRIN-1 protein that is specifically expressed on the surface of the cancer cell, and an antitumor agent, wherein the antibody and the antitumor agent are combined together or separately, and to a use of the medicament.

Claims (20)

1. A method for treating and/or preventing recurrence of a CAPRIN-1 expressing cancer, comprising:

administering a medicament to a subject suspected of having a cancer,

wherein the medicament comprises a combination of an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein, and one or two or more types of antitumor agents,

wherein the antibody or fragment and the antitumor agent or antitumor agents are combined together or separately,

wherein the antibody or fragment and the antitumor agent are not conjugated together,

wherein the cancer expresses the CAPRIN-1 protein on the cell surface of the cancer and the antibody or fragment binds specifically to the extracellular region of a CAPRIN-1 protein existing on the surface of a cancer cell.

2. The method according to claim 1 , wherein the antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein is an antibody or a fragment thereof which binds specifically to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37 in the extracellular region of the CAPRIN-1 protein existing on the surface of a cancer cell.

3. The method according to claim 1 , wherein the CAPRIN-1 protein is from a human.

4. The method according to claim 1 , wherein the above antitumor agent is selected from one or more of the group consisting of: paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, thiotepa, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, triethylenephosphoramide, triethilenethiophosphoramide, trimethylolomelamine, bullatacin, bullatacinone, camptothecin, bryostatin, callystatin, cryptophycinl, cryptophycin8, dolastatin, duocarmycin, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, dynemicin, clodronate, esperamicin, aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin, detorbicin, 6-diazo-5-oxo-L-norleucine, adriamycin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacitidine, 6-azauridine (azauridine), carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone, aldophosphamideglycoside, aminolaevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfornithine, elliptinium acetate (elliptinium), epothilone, etoglucid, lenthinan, lonidamine, maytansine, ansamitocine, mitoguazone, mitoxantrone, mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid, 2-ethyl hydrazide, procarbazine, razoxane, rhizoxin, schizophyllan, spirogermanium, tenuazonic acid, triaziquone, roridine A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, docetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, oxaliplatin, carboplatin, vinblastine, etoposide, ifosfamide, mitoxanthrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin, aminopterin, xeloda, ibandronate, irinotecan, topoisomerase inhibitor, difluoromethylolnitine (DMFO), retinoic acid, capecitabine, and pharmaceutically acceptable salts and derivatives thereof.

5. The method according to claim 1 , wherein the antitumor agent is selected from the group consisting of cyclophosphamide, paclitaxel, docetaxel, vinorelbine, and pharmaceutically acceptable salts and derivatives thereof.

6. The method according to claim 1 , wherein the antibody is selected from the group consisting of single chain antibodies (scFv), Fab, F(ab′) 2 , and Fv.

7. The method according to claim 1 , wherein the antibody is a human antibody, humanized antibody, chimeric antibody, single chain antibody, or bispecific antibody.

8. The method according to claim 1 , wherein the above antitumor agent is one or more androgens.

9. A method for treating and/or preventing recurrence of a CAPRIN-1 expressing cancer, comprising

administering a medicament to a subject suspected of having a cancer,

wherein the medicament comprises a combination of an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein, and one or two or more types of antitumor agents,

wherein the antibody or fragment and the antitumor agent or antitumor agents are combined together or separately,

wherein the antibody or fragment and the antitumor agent are not conjugated together,

wherein the cancer expresses the CAPRIN-1 protein on the cell surface of the cancer, and

wherein the antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein is an antibody or a fragment thereof which binds specifically to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37 in the extracellular region of the CAPRIN-1 protein existing on the surface of a cancer cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2012
From: IDO, TAKAYOSHI; OKANO, FUMIYOSHI; NARITA, YOSHINORI
To: TORAY INDUSTRIES, INC.
Reel/Frame 028729/0054 →
Priority Claims (1)
JP 2010-023455 · Feb 4, 2010 · national
Continuity (1)
Related Publication 20120294860A1 · Nov 22, 2012